Skip to content

Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households

Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households: A Case-control Study of Exposure Risk at Home

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07369414
Acronym
NTMecoCF
Enrollment
120
Registered
2026-01-27
Start date
2026-02-16
Completion date
2030-12-01
Last updated
2026-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis (CF), Mucoviscidosis, Mycobacterium Abscessus Infection, Non-Tuberculous Mycobacteria

Keywords

Environmental reservoirs, Household water systems, Microbial exposure, Whole-genome sequencing, Environmental risk factors

Brief summary

This multicenter, non-interventional case-control study investigates whether household environmental reservoirs, particularly water systems, are associated with non-tuberculous mycobacterial (NTM) infections in people with cystic fibrosis (CF). Environmental samples from the homes of CF patients with and without NTM infection will be analyzed and genetically compared with available clinical isolates, alongside assessment of environmental risk factors, to improve understanding of exposure pathways and inform future prevention strategies.

Detailed description

This multicenter, non-interventional case-control study investigates whether domestic environmental reservoirs-particularly household water systems-contribute to non-tuberculous mycobacterial (NTM) infections in people with cystic fibrosis (CF). Approximately 120 CF patients from several centers in Germany will be enrolled, including 60 patients with a current or previous pulmonary NTM infection and 60 CF patients without known NTM infection as controls. Environmental samples (water, dust, and soil) will be collected from participants' households and analyzed for the presence of NTM using culture-based methods, PCR, and whole-genome sequencing. These findings will be compared between case and control households, and genetic similarity between environmental NTM isolates and available clinical isolates from the same patients will be assessed. In addition, standardized questionnaires will capture environmental and behavioral risk factors associated with NTM occurrence. The study is purely observational and relies on clinical data and isolates obtained through routine CF care, with no additional medical procedures for participants. Over a follow-up period of up to three years, newly occurring NTM infections in initially unaffected patients will be documented. The results aim to improve understanding of environmental exposure risks for NTM in CF and to provide evidence for future prevention strategies and potential guideline recommendations.

Interventions

OTHERMulti-modal NTM diagnostic including PCR, WGS, culture

Environmental samples from participants' households (e.g., water, dust, and soil) will be collected and tested for the presence of NTM. Analyses will be performed using PCR, culture-based methods, whole-genome sequencing (WGS), and subsequent bioinformatic analyses. In addition, available clinical NTM isolates from previous or future routine diagnostics will be included. If genomic sequencing has not yet been performed for these isolates, retrospective molecular genetic analysis (e.g., by WGS) will be conducted within the study to enable comparison with environmental isolates.

Sponsors

Research Center Borstel
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Confirmed diagnosis of cystic fibrosis (CF) * No age restriction (including minors with consent from legal guardians) * Written informed consent to participate in the study (or consent provided by a legal guardian for minors) * In the case of an NTM infection: diagnosis according to ATS/IDSA criteria and availability of a clinical NTM isolate

Exclusion criteria

* Lack of capacity to provide informed consent, refusal to participate, or withdrawal of informed consent

Design outcomes

Primary

MeasureTime frameDescription
Prevalence of NTM in environmental samplesDecember 2030Proportion of households of CF patients with and without NTM infection in which at least one (clinically relevant) NTM is detected in environmental samples (water, dust, soil).
Difference in NTM prevalence between case and control groupsDecember 2030Statistically significant difference in the frequency of NTM detection (clinically relevant and/or all NTM) in environmental samples between case group and control group.
Genetic concordance between environmental and patient isolatesDecember 2030Evidence of genetic relatedness (e.g., cgMLST clustering) between NTM detected in the household environment and clinical isolates from the same individual.

Secondary

MeasureTime frameDescription
Characterization of NTM species from environmental samplesDecember 2030Identification and taxonomic classification of NTM isolates using WGS, including typing (e.g., subspecies assignment for M. avium).
Identification of environmental and behavioral factors associated with NTM detectionDecember 2030Determination of significant risk factors (e.g., use of specific water sources, pet ownership, hygiene practices) based on questionnaire data and multivariable analyses.
Long-term outcomes (control group only)December 2030Proportion of patients without an initial NTM infection who develop a clinically relevant NTM infection during the follow-up period (up to 30 months), potentially in association with prior detection of NTM in the household environment.

Countries

Germany

Contacts

CONTACTMargo Diricks, PhD
mdiricks@fz-borstel.de+49 4537 / 188-7540
CONTACTNiklas Koehler, Dr. med.
studienzentrum@fz-borstel.de+49 4537 188 8080
PRINCIPAL_INVESTIGATORAlexander Mischnik, Prof. Dr. med.

National and WHO-Supranational Reference Center for Mycobacteria, Research Center Borstel, Leibniz Lung Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 20, 2026